Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Intra-Cellular Therapies Inc ITCI

Healthcare Psychedelics
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders. The Company leverages intracellular approach to develop treatments for people living with complex psychiatric and neurologic diseases. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical... see more

Recent & Breaking News (NDAQ:ITCI)

CAPLYTA® (lumateperone) Open-Label Safety Switching Study in Patients with Schizophrenia Published in the Journal, Schizophrenia Research

GlobeNewswire January 21, 2021

Intra-Cellular Therapies to Present at the 39th Annual J.P. Morgan Healthcare Conference

GlobeNewswire January 5, 2021

Intra-Cellular Therapies Announces the Initiation of Clinical Trials for ITI-LLAI, a Long-Acting Injectable Formulation of Lumateperone for the Treatment of Schizophrenia and for ITI-333, a Novel Treatment for Opioid Use Disorder

GlobeNewswire December 29, 2020

Intra-Cellular Therapies Highlights Lumateperone Presentations at the 59th Annual Meeting of the American College of Neuropsychopharmacology

GlobeNewswire December 9, 2020

Intra-Cellular Therapies to Present at the Evercore ISI 3rd Annual HealthCONx Conference

GlobeNewswire November 30, 2020

Intra-Cellular Therapies Reports Third Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire November 9, 2020

Intra-Cellular Therapies to Host Third Quarter 2020 Financial Results Conference Call and Webcast

GlobeNewswire November 4, 2020

New Ventures Funds Rebrands as Scientia Ventures

PR Newswire October 2, 2020

Intra-Cellular Therapies Announces the Appointment of Dr. Suresh Durgam as Chief Medical Officer

GlobeNewswire October 1, 2020

Intra-Cellular Therapies to Present at the Morgan Stanley 18th Annual Global Healthcare Conference

GlobeNewswire September 15, 2020

Intra-Cellular Therapies to Present at the Cantor Virtual Global Healthcare Conference

GlobeNewswire September 14, 2020

Intra-Cellular Therapies Prices Public Offering of Common Stock

GlobeNewswire September 10, 2020

Intra-Cellular Therapies Announces Proposed Public Offering of Common Stock

GlobeNewswire September 9, 2020

Intra-Cellular Therapies Announces Positive Topline Results from Study 402 Evaluating Lumateperone as Adjunctive Therapy in Patients with Bipolar Depression

GlobeNewswire September 9, 2020

Intra-Cellular Therapies Reports Second Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire August 10, 2020

Intra-Cellular Therapies to Host Second Quarter 2020 Financial Results Conference Call and Webcast

GlobeNewswire August 4, 2020

Intra-Cellular Therapies Announces Positive Top-line Results from ITI-214 Phase I/II Study in Patients with Heart Failure

GlobeNewswire June 29, 2020

Intra-Cellular Therapies to Present at the 2020 RBC Capital Markets Global Healthcare Conference

GlobeNewswire May 14, 2020

Intra-Cellular Therapies to Host Virtual Annual Meeting of Stockholders

GlobeNewswire May 13, 2020

Intra-Cellular Therapies Reports First Quarter 2020 Financial Results and Provides Corporate Update

GlobeNewswire May 7, 2020